Complete financial analysis of Tetra Bio-Pharma Inc. (TBPMF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tetra Bio-Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ambea AB (publ) (0RNX.L) Income Statement Analysis – Financial Results
- Argus Capital Corp. (ARGUW) Income Statement Analysis – Financial Results
- Baid Finserv Limited (BAIDFIN.NS) Income Statement Analysis – Financial Results
- Banco da Amazônia S.A. (BAZA3.SA) Income Statement Analysis – Financial Results
- GiG Software PLC (GIG-SDB.ST) Income Statement Analysis – Financial Results
Tetra Bio-Pharma Inc. (TBPMF)
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 112.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 67.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 44.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 39.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.94M | 11.65M | 6.20M | 5.96M | 2.06M | 263.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.25M | 8.77M | 7.64M | 5.66M | 4.33M | 719.17K | 473.82K | 310.23K | 153.82K | 285.96K | 377.50K | 250.98K | 298.81K | 467.53K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 603.44K | 0.00 | 106.39K | 109.71K | 40.10K | 12.09K | 115.75K | 130.80K | 8.76K | 23.20K | 48.63K | 0.00 |
| SG&A | 12.25M | 8.77M | 7.64M | 5.66M | 4.33M | 719.17K | 473.82K | 310.23K | 153.82K | 401.71K | 508.30K | 259.75K | 322.01K | 516.16K | 114.28K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 113.96K | -166.80K | 0.00 | 50.00K | 0.00 | 0.00 | 0.00 | 57.00 | 525.00 | 431.00 | 20.56K | 0.00 |
| Operating Expenses | 24.30M | 20.46M | 13.86M | 11.63M | 6.40M | 982.71K | 473.82K | 310.23K | 156.21K | 401.71K | 1.55M | 424.05K | 341.13K | 528.85K | 114.28K |
| Cost & Expenses | 24.30M | 20.46M | 13.86M | 11.70M | 6.40M | 982.71K | 473.82K | 310.23K | 156.21K | 401.71K | 1.55M | 424.05K | 341.13K | 528.85K | 114.28K |
| Interest Income | 105.03K | 98.01K | 89.77K | 113.96K | 487.00 | 55.76K | 4.13K | 225.00 | 1.89K | 3.52K | 6.04K | 341.00 | 331.00 | 7.32K | 93.00 |
| Interest Expense | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.95K | 34.39K | 27.48K | 7.20K | 7.20K | 22.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.73M | -19.91M | -13.36M | -15.20M | -6.09M | -912.70K | -415.70K | -206.11K | 1.80M | -398.19K | -1.33M | -337.36K | -308.04K | 656.08K | -114.28K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -13,528.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.84M | -19.94M | -13.39M | -15.20M | -6.10M | -912.70K | -415.70K | -206.11K | 1.80M | -398.19K | -1.33M | -337.36K | -308.04K | 656.08K | -114.28K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -13,535.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -27.33M | -1.21M | -860.16K | 3.73M | -597.61K | -61.45K | -8.13K | -104.12K | -1.96M | -229.17K | -445.53K | -86.16K | -32.66K | -1.16M | -20.00K |
| Income Before Tax | -52.18M | -21.15M | -14.25M | -7.85M | -6.70M | -996.97K | -594.78K | -414.13K | -2.11M | -627.35K | -1.77M | -423.52K | -340.70K | -508.28K | -134.28K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -6,990.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | 5.75M | 1.42M | -3.90M | -171.48K | -52.71K | 0.00 | 0.00 | 0.00 | -72.44K | -315.30K | 86.35K | 32.76K | 1.18M | -93.00 |
| Net Income | -52.18M | -26.48M | -15.28M | -7.57M | -6.23M | -944.26K | -594.78K | -414.13K | -2.11M | -554.91K | -1.46M | -509.87K | -373.46K | -1.69M | -134.18K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -6,741.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.12 | -0.10 | -0.08 | -0.05 | -0.06 | -0.01 | -0.01 | -0.01 | -0.08 | -0.02 | -0.08 | -0.04 | -0.05 | -0.32 | -0.04 |
| EPS Diluted | -0.12 | -0.10 | -0.08 | -0.05 | -0.06 | -0.01 | -0.01 | -0.01 | -0.08 | -0.02 | -0.08 | -0.04 | -0.05 | -0.32 | -0.04 |
| Weighted Avg Shares Out | 445.70M | 258.15M | 188.24M | 145.69M | 107.80M | 64.81M | 55.47M | 28.52M | 26.25M | 23.94M | 19.07M | 11.39M | 7.91M | 5.22M | 3.08M |
| Weighted Avg Shares Out (Dil) | 445.70M | 258.15M | 188.24M | 145.69M | 107.80M | 64.81M | 55.47M | 28.52M | 26.25M | 23.94M | 19.07M | 11.39M | 7.91M | 5.22M | 3.08M |
Tetra Bio-Pharma & Avicanna Enter Into Strategic Partnership
Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced that it has executed a non-binding term sheet with Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) to assess entering into a strategic partnership comprising of three strategic pillars, including: The registration and commercialization of...
Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials Of QIXLEEF For Cancer Pain
Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial clinical data from its ongoing Phase 2 clinical trials of QIXLEEF™ (REBORN©1 and PLENITUDE©), which is a botanical inhaled investigational...
Tetra Bio-Pharma advancing breakthrough pain drug QIXLEEF to late clinical development stage
Tetra Bio-Pharma Inc shared a progress report on its development of its lead investigational drug QIXLEEF, a THC and CBD inhaled product for treatment of breakthrough pain. The pharmaceutical firm said it is finalizing its strategy to procure raw materials...
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
OTTAWA, ON, Oct. 14, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational...
Tetra Bio-Pharma says its first cannabinoid-derived medicine REDUVO is a ‘major milestone' as it gears up to launch it
Tetra Bio-Pharma Inc. said the company had achieved a “major milestone” through its first cannabinoid-derived medicine REDUVO as it announced that numerous pre-launch activities have been initiated in Canada.
Tetra Bio-Pharma draws positive Scientific Advice Assessment report for its cannabinoid-based drug candidate QIXLEEF
Tetra Bio-Pharma Inc, a cannabinoid-derived drug discovery and development company, revealed that it received positive feedback from a Scientific Advice Assessment (SAA) report from the Malta Medicines Authority on its drug development plan for QIXLEEF and eligibility for submitting a...
Tetra Bio-Pharma receives positive Scientific Advice Assessment report for its cannabinoid-based drug candidate QIXLEEF
Tetra Bio-Pharma Inc, a cannabinoid-derived drug discovery and development company, revealed that it received positive feedback from a Scientific Advice Assessment (SAA) report from the Malta Medicines Authority on its drug development plan for QIXLEEF and eligibility for submitting a...
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
SAA Report endorsed Tetra Bio-Pharma's proposed nonclinical development and quality programs for QIXLEEF™. SAA Report provides clarity on clinical requirements for registration in Europe.
Tetra Bio-Pharma files a PCT patent application for 'Cannabis Plant Residue and Use Thereof'
Tetra Bio-Pharma Inc. said it has filed a PCT patent application for 'Cannabis Plant Residue and Use Thereof', under PCT Patent Application No.
Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use...
Source: https://incomestatements.info
Category: Stock Reports